Clinical Trials

Our Clinical Trials

About Marrow-Infiltrating Lymphocytes (MILs®)

Patients with cancer have cells in their bone marrow called memory T cells that can recognize, find and eliminate those cancer cells. WindMIL collects bone marrow containing these memory T cells through a short procedure that does not require hospitalization. Using WindMIL’s technology, the patient’s cells are converted and activated into marrow-infiltrating lymphocytes (MILs®) – a novel, cancer-fighting cell therapy. The MILs can potentially identify and kill the patient’s cancerous tumor.

Clinical Trials

Research suggests that MILs have the potential to recognize and treat numerous cancers including lung, bladder, breast, glioblastoma, head and neck, melanoma, prostate, renal cell (kidney), hepatocellular (liver) and others. WindMIL is working with cancer centers throughout the United States to develop MILs for the treatment of cancer.

Currently Enrolling

Non-small Cell Lung Cancer Phase 2 Clinical Trial

WindMIL is currently enrolling patients for a Phase 2 clinical trial focused on non-small cell lung cancer (NSCLC), specifically patients with locally advanced and unresectable or metastatic NSCLC that have been previously treated. To learn more about this trial, click here.

If you or a loved one has been diagnosed with NSCLC and would like to learn more about qualifying for WindMIL’s NSCLC clinical trial, you can learn more here.

Phase 0 Studies

WindMIL is also recruiting patients for several Phase 0 studies which are designed to collect bone marrow from patients with a variety of different tumor types to help us evaluate generating MILs for these cancers. There are not studies that will treat your cancer, however will help cancer research. These studies are focused on:

  • Glioblastoma: University of California – Irvine and University of California – Davis
  • Head and neck cancer: University of Michigan Rogel Cancer Center
  • Breast cancer: Providence Cancer Institute in Portland, Oregon
  • Renal and urothelial cancer: Stephenson Cancer Center at Oklahoma University Medicine
  • Renal cell carcinoma, melanoma, colon and urothelial cancers: University of California – Davis

If you or a loved one is interested in participating in one of our Phase 0 studies, you may reach out to the following:

  • Glioblastoma:
    • University of California – Irvine
Contact the clinical research supervisor via email tyassear@ucdavis.edu or phone (916) 734-0753
    • University of California – Davis
Contact Alex Murray, Assistant Clinical Research Coordinator via email admurry@hs.uci.edu
  • Head and neck cancer: Contact the primary investigator, Dr. Paul Swiecicki, at the University of Michigan Rogel Cancer Center via email pswiecic@med.umich.edu
  • Breast cancer: Contact the Providence Cancer Institute in Portland, OR at (503) 215-2614
  • Renal and urothelial cancer: Contact the Stephenson Cancer Center at Oklahoma University Medicine at SCC-IIT-Office@ouhsc.edu
  • Renal cell carcinoma, melanoma, colon and urothelial cancers: Contact the clinical research supervisor via email tyassear@ucdavis.edu or phone (916) 734-0753